Among her many contributions to this field are studies that led to the establishment of combining the drug epirubicin with 2 other chemotherapy drugs as a standard treatment for premenopausal women with breast cancer. She also conducted research that reduced side effects and increased the effectiveness of tamoxifen in postmenopausal women with breast cancer – work that led to a dramatic change in how women are treated for the disease.

Dr. Klotz obtained his medical degree from the University of Toronto and completed his residency at the University of Toronto Gallie Program in Surgery. Dr. Klotz continued his postgraduate studies with a special fellowship at Memorial Sloan Kettering Cancer Centre in New York in uro-oncology and tumour biology.

Dr. Klotz is a widely published uro-oncologist who serves on the board or heads many medical/scientific organizations and committees.

Dr. Dan Hoth is a medical oncologist with more than twenty five years experience in clinical development of investigational drugs in cancer and infectious disease.  He has provided drug development and clinical trial consulting for numerous biotechnology and pharmaceutical companies and most recently he served as senior vice president, development, and chief medical officer of Axys Pharmaceuticals.  Prior to that from 1993 to 1997 he held the position of Senior Vice President and Chief Medical Officer at Cell Genesys.                                                              

Dr. Hoth served at the National Cancer Institute from 1980-1987 as Chief, Investigational Drug Branch, responsible for all clinical investigations of IND stage anticancer pharmaceuticals.  Following that post he served from 1987-1993 as the Director, Division of AIDS at the National Institute of Allergy and Infectious Disease

He currently serves on several clinical/scientific advisory Boards, and the Board of Directors of three companies  He has participated in four NDAs.  He has experience developing small molecules, antibodies, cytokines, gene therapy, and vaccines. He has also served as a consultant to both the FDA and NIH in oncology drug development.  Before the NIH, he was on the faculty of the Georgetown University School of Medicine. Dr. Hoth received his M.D. from Georgetown University School of Medicine and A.B. in Psychology from Franklin and Marshall College.

Research directed by Stanley C. Jordan, MD, has led to major advances in diagnostic and treatment approaches in the care of patients receiving transplanted organs.

He developed a process that uses intravenous immunoglobulin (IVIG) to reduce the risk of rejection in difficult cases in which other medications have failed. He also created a technique to detect post-transplant lymphoproliferative disorder (PTLD) in its earliest stages, when intervention is most effective. (PTLD is a form of cancer that can have catastrophic effects on children who receive donated organs.)

For more than two decades, Dr. Jordan has performed extensive research into various aspects of immunology and transplantation, funded by dozens of research grants and awards, including two prestigious National Institutes of Health controlled clinical trials in kidney transplantation grants. He has written hundreds of articles and abstracts published in scientific journals, presented findings at medical and scientific organizations and authored about two dozen book chapters.

He was appointed in 1998 to a task force assembled by the National Institutes of Health's National Institute of Allergy and Infectious Diseases to advise Congress on the safety and efficacy of intravenous gammaglobulin products. He also served on another NIH/NIAID task force that was commissioned to develop research priorities for kidney transplantation for the 21st century. Among his numerous other appointments, he was a member of the American Society of Transplant Physicians/American Society of Transplant Surgeons task force on transplant tolerance induction in 1997.

Dr. Jordan maintains membership in local, national and international professional societies and has served on the editorial boards of numerous professional journals.

After receiving his undergraduate and medical degrees from the University of North Carolina, Chapel Hill, Dr. Jordan completed a pediatric internship and residency at the University of California, Los Angeles. He completed three fellowships: one in pediatric nephrology at UCLA, one in experimental pathology in the Department of Immunology at Scripps Clinic and Research Foundation, and the third in dialysis and transplantation at Children's Hospital of Los Angeles.

He is board certified in pediatrics, pediatric nephrology and diagnostic laboratory immunology. In addition to his responsibilities at Cedars-Sinai, Dr. Jordan serves as Professor of Pediatrics at UCLA School of Medicine.

Dr. Sacher is a nationally recognized expert and educator who has delivered and/or chaired more than 12 international and national presentations during the past academic year

Dr. Sacher is the fourth director in Hoxworth's 61-year history. He serves with numerous scientific organizations and professional societies, including the American Society of Hematology, American Clinical & Climatological Association, National Institutes of Health, American Association of Blood Banks, and American Red Cross. Dr. Sacher has authored several scientific journal articles, chapters, and abstracts.

Dr. Sacher also served as Interim Dean of the College of Medicine at the University of Cincinnati Academic Health Center from August 2004 to July 2005. Dr. Sacher previously served as Chairman of the Department of Laboratory Medicine and Director of Transfusion Medicine at Georgetown University Hospital and Professor of Medicine, Oncology and Pathology in the Hematology/Oncology division of the Department of Medicine. He was also an attending hematologist at Georgetown University Hospital and a Department of Pathology staff member.

Fintan Steele returned to the Broad Institute in 2008 as the Director of Communications, working the previous two years as Executive Vice President of the Life Sciences group for Feinstein Kean Healthcare where he worked with a variety of private and public clients in the molecular medicine field. Although he enjoyed his experience at Feinstein Kean Healthcare, he believes that "ultimately there is no place like the Broad Institute."

Fintan's background includes 16 years of experience in communicating the science and implications of genetics and genomics to a variety of audiences. Prior to his first tenure at Broad he was the Global Head of Communications for the Novartis Institutes for BioMedical Research. He also held several editorial positions for public and private scientific publishers, including News and News & Views editor for Nature Medicine, Executive Editor of the Journal of Clinical Investigation, and Executive Editor of Genomics and of Molecular Therapy.

After receiving his doctorate from the University of Notre Dame in South Bend, Ind., Fintan completed postdoctoral fellowships at the National Eye Institute, National Institutes of Health and at Johns Hopkins School of Medicine. He also holds a Masters of Divinity degree from St. Meinrad School of Theology as well as a Masters of Arts in Medical Ethics/Religious Studies from Indiana University, where he focused on ethical issues in genetic engineering.

Dr. Robert Feldman is a board certified urologist and medical director of the Connecticut Clinical Research Center. He has been involved in clinical research for over twenty years and has directed or participated in excess of 300 phase II to phase IV trials.

Dr. Feldman has served on many pharmaceutical advisory boards and has contributed in areas from protocol development to launch. He is a member of numerous local, national and international medical societies. A frequent contributor to the medical literature, Dr. Feldman has written extensively on urologic disease. He has received many invitations to speak in North America and around the world.

After graduating from Albert Einstein College of Medicine, Dr. Feldman interned at Medical College of Virginia then served as a flight Surgeon in the USAF and completed a residency at Yale New Haven Hospital.